Vaccine and antiviral development underway for rare Bundibugyo Ebola outbreak (bioworld.com)

• Animal studies in US and UK for new Bundibugyo vaccine
• Serum Institute of India ready for production
• Oral antiviral obeldesivir under evaluation as PEP
• Clinical trials expected in 2-3 months if successful

"Less than two weeks after the outbreak was officially declared, animal studies of a newly designed vaccine against the Bundibugyo Ebola virus are now underway in the U.S. and U.K. The Serum Institute of India is standing ready to manufacture the vaccine for clinical trials. If animal tests are positive, the vaccine will be ready for clinical trials in two to three months. The oral antiviral obeldesivir is also being evaluated as post-exposure prophylaxis."